Big firms to discuss introduction of biosimilar substitution in France
This article was originally published in Scrip
Some of the big guns of the biopharmaceutical and generics industries are to take part in a working group set up to determine just how biosimilar substitution is to be implemented in France, following the publication of the 2014 social security financing law (LFSS) allowing pharmacists to substitute a biosimilar for a prescribed biological in certain circumstances.
You may also be interested in...
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.
Europe’s Innovative Medicines Initiative is calling for R&D projects aimed at tackling the spread of COVID-19, saying that collaborative ventures have the potential to accelerate the development of therapeutics and diagnostics to tackle this and future coronavirus outbreaks.
Europe’s Innovative Medicines Initiative is to get €90m in funding for programs targeting the coronavirus outbreak.